Erel-Akbaba et al.[113] designed SLNs for the delivery of interfering RNAs against EGFR, a receptor known to modulate tumor cell proliferation, viability, and differentiation, and against PD-L1, a transmembrane protein involved in immune checkpoints overexpressed in several tumors. The gene discussed is CD274; the disease is neoplasm.